Department of Health vs. Philippine Tobacco Institute, Inc.

Tobacco products are "health products" under Section 10(ff) of RA No. 3720, as amended by RA No. 9711, by virtue of their effect on health, and the FDA retains regulatory authority over the health aspects of tobacco products not covered by special laws such as RA No. 9211. Section 25 of RA No. 9711 does not exclude tobacco products from FDA jurisdiction; it merely preserves the exclusive jurisdiction of other specialized agencies only insofar as the acts covered by those agencies' enabling laws.

The Department of Health (DOH) is the primary government agency responsible for formulating, planning, implementing, and coordinating policies and programs in the field of health, including the administration of all laws, rules, and regulations on health and food and drug safety. The Food and Drug Administration (FDA) is an attached agency of the DOH, originally established in 1963 under RA No. 3720, abolished in 1982 with functions transferred to the Bureau of Food and Drugs, and later reinforced and renamed the FDA under RA No. 9711 in 2009, which vested it with regulatory authority over all health products. Separately, RA No. 9211 (Tobacco Regulation Act of 2003) created the Inter-Agency Committee on Tobacco (IAC-Tobacco), chaired by the Secretary of Trade and Industry with the Secretary of Health as Vice Chairperson, vesting it with exclusive power to administer and implement that law. The Philippines is also a party to the WHO Framework Convention on Tobacco Control (WHO FCTC), signed on September 23, 2003 and ratified on June 6, 2005, obligating state parties to implement comprehensive tobacco control measures including protection of public health policies from tobacco industry interference. In 2011, pursuant to Section 22 of RA No. 9711, the DOH and FDA promulgated the Implementing Rules, which included Book II, Article III classifying tobacco products as health products under FDA regulatory authority.

The Philippine Tobacco Institute, Inc. (PTI), representing major tobacco companies, filed a Petition for Declaratory Relief with application for a temporary restraining order and/or writ of preliminary injunction before the Regional Trial Court of Las Piñas City, Branch 255. PTI sought to prohibit the enforcement of the Implementing Rules and Regulations of RA No. 9711 and to declare them void for allegedly disregarding RA No. 9711 and RA No. 9211, the Tobacco Regulation Act of 2003. PTI argued that under RA No. 9211, the IAC-Tobacco had exclusive jurisdiction over tobacco products, including their health aspect, and that Section 25 of RA No. 9711 explicitly prohibited the FDA from taking cognizance of health products already regulated by other agencies. PTI specifically contested Book II, Article III of the Implementing Rules, which classified tobacco products as "health products" and placed them under FDA regulatory authority, as well as other provisions in Book II covering licensing, labeling, and advertising that PTI claimed would encroach on the IAC-Tobacco's authority. PTI further argued that the restriction on FDA dealings with the tobacco industry under Section 2(b) lacked statutory basis and violated the equal protection clause, and that congressional deliberations revealed legislative intent to exclude tobacco products from the FDA's regulatory power.

The DOH and FDA countered that they validly exercised their rule-making power and regulatory authority, maintaining that tobacco products were "health products" under Section 10(ff) of RA No. 3720, as amended, due to their detrimental effects on health. They argued that Section 25 preserved FDA jurisdiction over all health products on matters not covered by special laws, that the IAC-Tobacco's powers were distinct from theirs, and that the provisions on protection against tobacco industry interference were consistent with the State's constitutional mandate and the Philippines' obligations under the WHO FCTC. Petitioners-intervenors Senators Cayetano and Drilon added that RA No. 9211 regulated only certain aspects of the tobacco industry and that the IAC-Tobacco's task was merely compliance monitoring and program development, while implementation lay with member-agencies. Respondent-intervenor Representative Lagman opposed the inclusion, arguing that tobacco products were not health products under the doctrine of ejusdem generis, that dual jurisdiction would spawn conflicts, and that the WHO FCTC was addressed principally to state parties' legislatures, not administrative bodies.

The RTC denied PTI's motion for injunction on September 28, 2011, and its motion for reconsideration on December 15, 2011. However, on January 27, 2012, the RTC ruled on the merits and granted PTI's petition. Relying on Section 25 of RA No. 9711, the trial court declared that tobacco products were expressly excluded from the coverage of the law and hence beyond the FDA's regulatory power. It recognized the IAC-Tobacco's exclusive jurisdiction over tobacco products under RA No. 9211 and ruled it improper for the DOH and FDA to include tobacco products under Book II, Article III of the Implementing Rules. The RTC relied on the testimony of Atty. Emilio Polig, Head of the FDA's Legal Department, during congressional deliberations, who opined that tobacco was covered by a special law and thus excluded from RA No. 9711. The RTC concluded that the DOH, as a member of the IAC-Tobacco through the FDA, could only regulate tobacco products through that committee by providing inputs and proposals, and that the DOH and FDA exceeded their rule-making powers in including the contested provisions. On March 29, 2012, the DOH and FDA, through the Office of the Solicitor General, filed the present Petition for Review before the Supreme Court.

• Regulatory Authority over Health Aspects: Petitioners argued that Section 25 of RA No. 9711 clearly provides that the law governs all health products except matters covered by special laws, thus the FDA retained regulatory powers over tobacco products on matters affecting public health not covered by RA No. 9211.
• Tobacco as Health Products: Petitioners maintained that tobacco products are "health products" under Section 10(ff) of RA No. 3720, as amended, due to their detrimental effects on health, and thus fall under FDA regulatory authority, notwithstanding the lack of a specific center under Section 5 to regulate tobacco products, as the FDA is empowered to create additional organizational units.
• DOH's Primary Health Responsibilities: Petitioners emphasized that the DOH's primary responsibilities of formulating and implementing health policies and programs were neither amended nor repealed by RA No. 9211, and that RA No. 9711 was enacted to strengthen the State's regulatory and enforcement capacity over health products, with the two laws not confusing or merging the functions of the FDA and the IAC-Tobacco.
• Protection Against Tobacco Industry Interference: Petitioners argued that Book II, Article III, Section 2(b), paragraph 2 of the Implementing Rules is consistent with DOH Memorandum Order No. 2010-0126 and Joint Memorandum Circular No. 2010-01, and conforms to the Philippines' obligations under the WHO FCTC to protect public health policies from the vested interests of the tobacco industry.
• Equal Protection: Petitioners argued that the tobacco industry's distinct classification rests on valid and reasonable standards and does not violate the equal protection clause.
• Legislative Intent: Petitioners-intervenors argued that congressional deliberations reveal the consensus of legislators was to include tobacco products within the coverage of RA No. 9711 and the FDA's regulatory authority, and that the trial court erroneously relied on a mere opinion by Atty. Polig, which was only a portion of the Bicameral Committee deliberations and not the Committee's intent.
• Suppletory Application: Petitioners-intervenors contended that Section 25 did not diminish petitioners' powers, as the proviso provides a limitation only insofar as certain acts have been covered by special laws; as to acts not covered, including the health aspect of tobacco products, RA No. 9711 has suppletory application and these remain within petitioners' regulatory authority.
• Ejusdem Generis Inapplicable: Petitioners-intervenors argued that ejusdem generis only applies in case of ambiguity and would not be controlling where the plain purpose and intent of the Legislature would thereby be hindered and defeated, and that restricting the law's coverage only to the enumerated list would defeat the law's objective.

• IAC-Tobacco's Exclusive Jurisdiction: Respondent argued that RA No. 9211 bestows on the IAC-Tobacco exclusive jurisdiction to regulate tobacco products, including their health aspect, and that the DOH cannot regulate tobacco products on its own, its authority being limited to membership in the IAC-Tobacco.
• Legislative Intent to Exclude Tobacco: Respondent contended that RA No. 9711, supported by congressional deliberations, points to legislative intent to exclude tobacco products from the law's coverage.
• Tobacco Not Health Products: Respondent argued that tobacco products are not health products, they not being mentioned in RA No. 9711, nor was a specific center created under the law to regulate them.
• Section 25 as Delimitation: Respondent argued that Section 25 delimited the FDA's jurisdiction by explicitly divesting it of power over matters already under the exclusive jurisdiction of other agencies, and that Congress decided not to give RA No. 9711 suppletory application to other special laws, as seen in the omission of such a clause in the final version.
• Encroachment on IAC-Tobacco: Respondent argued that the Implementing Rules unduly encroach on the IAC-Tobacco's exclusive jurisdiction over labeling, advertising, sponsorship, and marketing of tobacco products.
• WHO FCTC Not Self-Implementing: Respondent argued that the WHO FCTC is not self-implementing, meaning petitioners cannot use it as basis of any right or obligation.
• Equal Protection Violation: Respondent argued that the restriction on FDA dealings with the tobacco industry violates respondent's right to equal protection.
• Ejusdem Generis (Respondent-Intervenor): Respondent-intervenor argued that the second sentence of Section 10(ff) must be construed under ejusdem generis as akin in nature to the enumerated products, and that tobacco products are not germane to such class because, unlike the enumerated health products which have generally beneficial use, tobacco products have no health benefits.
• Absurd Results (Respondent-Intervenor): Respondent-intervenor argued that the FDA's assumption of jurisdiction over tobacco products would yield absurd results, as it would be incredible to ensure the "safety, efficacy, purity and quality" of tobacco products, which are hazardous, and that tobacco products remain legitimate articles of commerce which cannot be banned for failing to conform to FDA standards.
• Dual Jurisdiction Inimical (Respondent-Intervenor): Respondent-intervenor contended that dual jurisdiction would spawn conflicts and confusion inimical to the government's health agenda, and that it would be best for a specialized agency like the IAC-Tobacco to focus on tobacco as a particularly deleterious product.

• Validity of Implementing Rules: Whether the RTC correctly nullified the Rules and Regulations Implementing RA No. 9711 insofar as they included tobacco products and the tobacco industry in their coverage.
• Section 25 Coverage: Whether Section 25 of RA No. 9711 excludes the regulation of the health aspects of tobacco products from the FDA's authority.
• Tobacco as Health Products: Whether tobacco products are "health products" under the definition provided in Section 10(ff) of RA No. 3720, as amended by Section 9 of RA No. 9711.

• Validity of Implementing Rules: No. The RTC erred in nullifying the Implementing Rules; the DOH and FDA acted within their powers in including Book II, Article III, as they have technical authority over matters of public health and the Implementing Rules explicitly limit FDA rules to policy areas not covered by specialized agencies and special laws.
• Section 25 Coverage: No. Section 25 does not exclude the health aspects of tobacco products from FDA authority. The proviso merely preserves the exclusive jurisdiction of other agencies only insofar as acts are covered by special laws; matters not covered—including the health aspects of tobacco products—remain under the FDA's broad regulatory authority.
• Tobacco as Health Products: Yes. Tobacco products are "health products" under Section 10(ff) because they have an effect on health, and the second part of the definition gives the FDA discretionary authority to determine which products require regulation; the ejusdem generis principle does not apply as there is no ambiguity.

• Validity of Implementing Rules: The inclusion of tobacco products in the Implementing Rules is supported by the text of RA No. 9711, the Constitution (Article II, Section 15 and Article XIII, Section 12), pertinent congressional deliberations, and the Philippines' obligations under the WHO FCTC. The FDA, as an attached agency of the DOH, has both the mandate and the technical competence over matters of public health. There is no overlap of functions because the Implementing Rules explicitly state that the rules and regulations to be promulgated by the FDA will refer to policy areas not covered by specialized agencies and special laws. Respondent's proposed interpretation would effectively remove tobacco companies from petitioners' regulation and allow them to be principally regulated by the IAC-Tobacco, of which they are members, leading to an absurd result contrary to law and international obligations.

• Section 25 Coverage: Section 25 of RA No. 9711 establishes that the law covers all health products, except for acts covered by special laws. Exceptions are strictly construed and extend only as far as their language fairly warrants. Particular clauses and phrases of a statute should not be taken as detached and isolated expressions; the whole and every part must be considered. The IAC-Tobacco's implementing authority under RA No. 9211 is limited to the specific acts enumerated in that law—regulation of distribution, access, sale, labeling, advertisements, sponsorships, and promotions of tobacco products—and nothing in the law denotes authority over the health aspects of tobacco products. Conversely, under RA No. 9711, the FDA has regulatory authority over all health products, which include tobacco products. Section 25 preserves FDA regulatory authority as to the health aspect of tobacco products, it being beyond IAC-Tobacco's implementing authority. This interpretation is consistent with the rule that laws are interpreted to be in harmony with other laws on a similar subject to build a coherent system. Congressional deliberations of the Bicameral Conference Committee confirmed that the health aspects of tobacco, sugar, and coconut are within FDA regulatory authority, and that RA No. 9711 applies suppletorily to special laws with regard to health effects. The Court noted that Section 34 of RA No. 9211 even recognized the DOH's capability on matters of health, designating it to lead information dissemination on the harmful effects of smoking.

• Tobacco as Health Products: The definition in Section 10(ff) comprises two parts: the first enumerates specific products (food, drugs, cosmetics, devices, biologicals, vaccines, in-vitro diagnostic reagents, and household/urban hazardous substances), and the second is a general statement that health products "shall also refer to products that may have an effect on health which require regulations as determined by the FDA." The definition is clear, leaving no room for construction or interpretation, only application. Tobacco use and exposure to secondhand smoking pose health hazards causing death and disease. The second part of the definition gives the FDA discretionary authority to determine which products require regulation. The ejusdem generis principle does not apply because there is no ambiguity, and restricting "health products" to the enumerated list or the same class would hinder the lawmaker's intent of strengthening the FDA's regulatory authority under RA No. 9711. A contrary reading—that the FDA could regulate cosmetics due to their effects on health but not tobacco products—would be illogical.

• Statutory Construction — Strict Construction of Exceptions — Exceptions in statutes are strictly construed and extend only as far as their language fairly warrants. Applied to Section 25 of RA No. 9711: the exception preserving other agencies' jurisdiction extends only to acts covered by special laws, not to all aspects of the products regulated by those agencies' enabling laws.

• Statutory Construction — Harmonious Interpretation — Laws are interpreted not only to be consistent throughout their provisions but also to be in harmony with other laws on a similar subject, to build a coherent system. Applied to construe RA No. 9711 and RA No. 9211 as complementary rather than conflicting, with the FDA retaining authority over the health aspects of tobacco products while the IAC-Tobacco retains authority over the acts enumerated in RA No. 9211.

• Statutory Construction — Ejusdem Generis — The ejusdem generis principle applies only in case of ambiguity and would not control where restricting a general term to an enumerated list would hinder the lawmaker's intent. Applied to reject the argument that tobacco products are excluded from the definition of "health products" under Section 10(ff), because the definition is clear and unambiguous, and restricting it to the enumerated list would defeat the objective of strengthening the FDA's regulatory authority.

• Statutory Construction — Plain Meaning Rule — Where the language of a statute is clear and unambiguous, there is no room for construction or interpretation, but only application. Applied to Section 10(ff), whose two-part definition clearly encompasses products that may have an effect on health.

• Treaty Law — Transformation Method — Treaties become part of domestic law through transformation pursuant to Article VII, Section 21 of the Constitution, following Senate concurrence by at least two-thirds of all members. Following ratification, no further legislative or executive action is necessary, and the whole government—including the judiciary—is duty-bound to abide by the treaty under the maxim pacta sunt servanda. Applied to the WHO FCTC, which has the force and effect of a statute and binds the DOH and FDA in exercising their regulatory powers over health products.

• "The mere acknowledgment in Section 25 of Republic Act No. 9711 that nothing in that law 'shall be deemed to modify the sole and exclusive jurisdiction of other specialized agencies[,]' such as the IAC-Tobacco under Republic Act No. 9211, does not automatically place tobacco products outside the Food and Drug Administration's regulatory authority. Quite the contrary, the IAC-Tobacco's authority under Republic Act No. 9211 does not cover the regulation of the health aspects of tobacco products." — This passage articulates the core ratio decidendi on the scope and effect of Section 25's proviso, distinguishing the IAC-Tobacco's limited implementing authority from the FDA's broader regulatory mandate over health aspects.

• "It is evident from Republic Act No. 9211 that the IAC-Tobacco has limited jurisdiction over tobacco products and does not regulate all their aspects. Its implementing authority is only restricted to the acts provided under the law, which mainly include the regulation of distribution, access, sale, labeling, advertisements, sponsorships, and promotions of tobacco products. Nothing in the law denotes that it holds authority over the health aspects of tobacco products." — This passage defines the boundary between the IAC-Tobacco's and the FDA's respective jurisdictions, establishing that RA No. 9211's coverage is act-specific, not product-comprehensive.

• "Respondent, representing major transnational tobacco companies in this country, proposes an interpretation of our law that will effectively remove them from petitioners' regulation. Its desired interpretation allows for tobacco companies to be principally regulated by the IAC-Tobacco, of which they happen to also be members. This not only leads to an absurd result, but it is also contrary to law and our international obligations." — This passage highlights the practical absurdity and self-serving nature of respondent's proposed interpretation, underscoring the conflict of interest inherent in tobacco industry membership in the IAC-Tobacco.

• "Section 10(ff) comprises two parts. The first part refers to an enumeration of specific products considered as health products. The second part is a general statement that health products 'shall also refer to products that may have an effect on health which require regulations as determined by the FDA.'" — This passage sets out the analytical framework for interpreting the statutory definition of "health products," establishing the two-part structure that brings tobacco products within FDA jurisdiction.

• Nazareth vs. Villar, 702 Phil. 319 (2013) — Cited for the rule that exceptions are strictly construed and extend only as far as their language fairly warrants. Applied to Section 25 of RA No. 9711 to hold that the proviso's exception preserves other agencies' jurisdiction only as to acts covered by special laws, not as to all aspects of regulated products.

• Gaanan vs. Intermediate Appellate Court, 229 Phil. 139 (1986) — Cited for the rule that particular clauses and phrases of a statute should not be taken as detached and isolated expressions, but the whole and every part thereof must be considered in fixing the meaning of any of its parts. Applied to reject respondent's truncated reading of Section 25.

• Dreamwork Construction, Inc. vs. Janiola, 609 Phil. 245 (2009) — Cited for the rule that laws are interpreted to be consistent throughout and in harmony with other laws on a similar subject, to build a coherent system. Applied to construe RA No. 9711 and RA No. 9211 as complementary.

• David vs. Senate Electoral Tribunal, 795 Phil. 529 (2016) — Cited for the doctrine that treaties become part of domestic law through transformation pursuant to Article VII, Section 21 of the Constitution, and that following Senate ratification, no further action is necessary and the whole government is duty-bound under pacta sunt servanda. Applied to establish the WHO FCTC's binding force as part of national law.

• Pharmaceutical and Health Care Association of the Philippines vs. Duque III — Cited for the principle that international law can become part of domestic law through transformation or incorporation, and that treaties have the force and effect of statute upon Senate concurrence. Applied alongside David to establish the WHO FCTC's domestic legal effect.

• In re Catholic Archbishop of Manila vs. Social Security Commission, 110 Phil. 606 (1961) — Cited in relation to the principle that ejusdem generis would not control where its application would hinder legislative intent. Applied to reject respondent-intervenor's ejusdem generis argument.

• Wyeth Philippines, Inc. vs. Construction Industry Arbitration Commission, G.R. Nos. 220045-48, June 22, 2020 — Cited for the principle that where a statutory definition is clear, there is no room for construction or interpretation, but only application. Applied to Section 10(ff)'s definition of "health products."

• Article II, Section 15, 1987 Constitution — "The State shall protect and promote the right to health of the people and instill health consciousness among them." Applied as constitutional basis for RA No. 9711 and the FDA's regulatory authority over health products, including tobacco products.

• Article XIII, Section 12, 1987 Constitution — "The State shall establish and maintain an effective food and drug regulatory system and undertake appropriate health manpower development and research, responsive to the country's health needs and problems." Applied as constitutional mandate supporting the promulgation and enforcement of the Implementing Rules regulating tobacco products.

• Article VII, Section 21, 1987 Constitution — "No treaty or international agreement shall be valid and effective unless concurred in by at least two-thirds of all the Members of the Senate." Applied to establish that the WHO FCTC became part of domestic law upon Senate ratification, binding the whole government.

• Section 25, RA No. 9711 — Coverage provision stating the Act governs all health products, provided that nothing shall modify the exclusive jurisdiction of other specialized agencies and special laws only insofar as acts covered by those agencies and laws, expressly including RA No. 9211. Interpreted as preserving FDA authority over matters not covered by special laws, including the health aspects of tobacco products, with the exception strictly construed.

• Section 10(ff), RA No. 3720, as amended by Section 9, RA No. 9711 — Defines "health products" as including enumerated items and "products that may have an effect on health which require regulations as determined by the FDA." Applied to classify tobacco products as health products by virtue of their harmful effects on health, with the second sentence giving the FDA discretionary authority to determine which products require regulation.

• Section 29, RA No. 9211 — Creates the IAC-Tobacco with "exclusive power and function to administer and implement" RA No. 9211. Interpreted as limited to the specific acts enumerated in RA No. 9211 (distribution, access, sale, labeling, advertisements, sponsorships, and promotions), not extending to the health aspects of tobacco products.

• Section 3, Administrative Code (Book IV, Title IX, Chapter 1) — Enumerates the DOH's powers and functions, including defining national health policy, providing health programs, and administering all laws, rules, and regulations in the field of health. Applied to confirm the DOH's primary responsibility for health matters, which was neither amended nor repealed by RA No. 9211.

• Sections 3 and 4, Book II, Article III, Implementing Rules of RA No. 9711 — Provide that nothing in the FDA Act shall modify the jurisdiction of other specialized agencies except the health aspects of such products, and that the FDA shall identify policy areas not covered by specialized agencies and special laws. Applied to demonstrate that the Implementing Rules themselves acknowledge and respect the boundary between FDA and other agencies' jurisdictions while expressly preserving FDA authority over health aspects.

• Carandang, Inting, Zalameda, M. Lopez, Gaerlan, Rosario, and J. Lopez, JJ., concur.
• Perlas-Bernabe, J. — filed a concurring opinion (text not provided in the source material).
• Lazaro-Javier, J. — filed a separate concurring opinion (text not provided in the source material).

• Caguioa, J. — Filed a dissenting opinion. Chief Justice Gesmundo joined this dissent. The text of the dissent is not provided in the source material; the basis of disagreement cannot be ascertained from the ponencia alone.
• Hernando, J. — Filed a dissenting opinion. The text of the dissent is not provided in the source material; the basis of disagreement cannot be ascertained from the ponencia alone.